Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screening

Cell Death and Disease

Volumn 5, Issue 6, 2014, Pages

  Liu, L J ^a   Leung, K H ^b   Chan, D S H ^b   Wang, Y T ^a   Ma, D L ^b   Leung, C H ^a  

^a Macau University of Science and Technology   (Macao)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

NATURAL PRODUCT; PROTEIN INHIBITOR OF ACTIVATED STAT; STAT1 PROTEIN; STAT3 INHIBITOR; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; STAT1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DIMERIZATION; DNA BINDING; DNA SEQUENCE; DRUG SCREENING; HELA CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; GENETICS; METABOLISM; PROCEDURES; PROTEIN MULTIMERIZATION; SRC HOMOLOGY DOMAIN;

ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HEP G2 CELLS; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEIN MULTIMERIZATION; SRC HOMOLOGY DOMAINS; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR;

EID: 84903755855     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.250     Document Type: Article

References (70)

1. Sehgal PB. Paradigm shifts in the cell biology of STAT signaling. Semin Cell Dev Biol 2008; 19: 329-340.
2. Levy DE, Inghirami G. STAT3: a multifaceted oncogene. Proc Natl Acad Sci USA 2006; 103: 10151-10152.
3. Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007; 251: 199-210.
4. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci 2009; 1171: 59-76.
5. Lai R, Rassidakis GZ, Medeiros LJ, Leventaki V, Keating M, McDonnell TJ. Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumours. J Pathol 2003; 199: 84-89.
6. Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 2006; 6: 231-241.
7. Furqan M, Mukhi N, Lee B, Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res 2013; 1: 5-14.
8. Johnston PA, Grandis JR. STAT3 signaling: anticancer strategies and challenges. Mol Interv 2011; 11: 18-26.
9. Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005; 11: 595-596.
10. Furqan M, Akinleye A, Mukhi N, Mittal V, Chen Y, Liu D. STAT inhibitors for cancer therapy. J Hematol Oncol 2013; 6: 90-100.
11. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
12. Fu XY. STAT3 in immune responses and inflammatory bowel diseases. Cell Res 2006; 16: 214-219.
13. Egwuagu CE. STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. Cytokine 2009; 47: 149-156.
14. Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov 2013; 12: 611-629.
15. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374: 1-20.
16. Yang JB, Huang J, Dasgupta M, Sears N, Miyagi M, Wang BL et al. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci USA 2010; 107: 21499-21504.
17. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007; 178: 2623-2629.
18. Wormald S, Hilton DJ. Inhibitors of cytokine signal transduction. J Biol Chem 2004; 279: 821-824.
19. Shuai K. Regulation of cytokine signaling pathways by PIAS proteins. Cell Res 2006; 16: 196-202.
20. Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 2008; 19: 414-422.
21. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999; 59: 5059-5063.
22. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 2007; 104: 7391-7396.
23. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004; 23: 8017-8023.
24. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006; 66: 3162-3168.
25. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Invest Drugs 2009; 18: 45-56.
26. Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 2001; 276: 45443-45455.
27. Jing N, Zhu Q, Yuan P, Li Y, Mao L, Tweardy DJ. Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol Cancer Ther 2006; 5: 279-286.
28. Weerasinghe P, Garcia GE, Zhu Q, Yuan P, Feng L, Mao L et al. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int J Oncol 2007; 31: 129-136.
29. Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005; 24: 970-979.
30. Turkson J, Zhang S, Mora LB, Burns A, Sebti S, Jove R. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 2005; 280: 32979-32988.
31. Ma DL, Liu LJ, Leung KH, Chen YT, Zhong HJ, Chan DSH et al. Antagonising STAT3 Dimerization by a Rhodium(III) Complex. Angew Chem Int Ed Engl 2014; e-pub ahead of print 30 May 2014; doi:10.1002/anie.201404686.
32. Szelag M, Sikorski K, Czerwoniec A, Szatkowska K, Wesoly J, Bluyssen HA. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity. Eur J Pharmacol 2013; 720: 38-48.
33. Li T, Wang W, Chen H, Li T, Ye L. Evaluation of anti-leukemia effect of resveratrol by modulating STAT3 signaling. Int Immunopharmacol 2010; 10: 18-25.
34. Regis G, Pensa S, Boselli D, Novelli F, Poli V. Ups and downs: The STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol 2008; 19: 351-359.
35. Lee HM, Chan DSH, Yang F, Lam HY, Yan SC, Che CM et al. Identification of natural product Fonsecin B as a stabilizing ligand of c-myc G-quadruplex DNA by high-throughput virtual screening. Chem Commun (Camb) 2010; 46: 4680-4682.
36. Chan DSH, Lee HM, Yang F, Che CM, Wong CCL, Abagyan R et al. Structure-based discovery of natural-product-like TNF-alpha inhibitors. Angew Chem Int Ed Engl 2010; 49: 2860-2864.
37. Leung CH, Chan DSH, Yang H, Abagyan R, Lee SMY, Zhu GY et al. A natural product-like inhibitor of NEDD8-activating enzyme. Chem Commun (Camb) 2011; 47: 2511-2513.
38. Zhong HJ, Ma VPY, Cheng Z, Chan DSH, He HZ, Leung KH et al. Discovery of a natural product inhibitor targeting protein neddylation by structure-based virtual screening. Biochimie 2012; 94: 2457-2460.
39. Ma DL, Chan DSH, Leung CH. Drug repositioning by structure-based virtual screening. Chem Soc Rev 2013; 42: 2130-2141.
40. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012; 75: 311-335.
41. Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998; 394: 145-151.
42. Tu SP, Jin H, Shi JD, Zhu LM, Suo Y, Lu G et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res (Phila) 2012; 5: 205-215.
43. Nam S, Xie J, Perkins A, Ma Y, Yang F, Wu J et al. Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells. Mol Oncol 2012; 6: 484-493.
44. Shakibaei M, Harikumar KB, Aggarwal BB. Resveratrol addiction: to die or not to die. Mol Nutr Food Res 2009; 53: 115-128.
45. Kim JE, Kim HS, Shin YJ, Lee CS, Won C, Lee SA et al. LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression. Exp Mol Med 2008; 40: 514-522.
46. Gupta SC, Kannappan R, Reuter S, Kim JH, Aggarwal BB. Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci 2011; 1215: 150-160.
47. Yeung K-S. Furans and Benzofurans. Top Heterocycl Chem 2012; 29: 47-76.
48. Chen Y, Chen S, Lu X, Cheng H, Ou Y, Cheng H et al. Synthesis, discovery and preliminary SAR study of benzofuran derivatives as angiogenesis inhibitors. Bioorg Med Chem Lett 2009; 19: 1851-1854.
49. Hayakawa I, Shioya R, Agatsuma T, Sugano Y. Synthesis and evaluation of 3-methyl-4-oxo-6-phenyl-4,5,6,7-tetrahydrobenzofuran-2-carboxylic acid ethyl ester derivatives as potent antitumor agents. Chem Pharm Bull (Tokyo) 2005; 53: 638-640.
50. Song H, Wang RX, Wang SM, Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 2005; 102: 4700-4705.
51. Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC et al. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res 2009; 69: 193-202.
52. Miyoshi K, Takaishi M, Nakajima K, Ikeda M, Kanda T, Tarutani M et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest Dermatol 2011; 131: 108-117.
53. Shen WJ, Zhang YH, Li W, Cong J, Zhou Y, Ng EHY et al. Effects of tanshinone on hyperandrogenism and the quality of life in women with polycystic ovary syndrome: protocol of a double-blind, placebo-controlled, randomised trial. BMJ Open 2013; 3: 1-6.
54. Siddiquee KAZ, Gunning PT, Glenn M, Katt WP, Zhang S, Schroeck C et al. An oxazolebased small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol 2007; 2: 787-798.
55. Onimoe GI, Liu AG, Lin L, Wei CC, Schwartz EB, Bhasin D et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs 2012; 30: 916-926.
56. Fossey SL, Bear MD, Lin JY, Li CL, Schwartz EB, Li PK et al. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. BMC Cancer 2011; 11: 112-126.
57. Zhang XL, Yue PB, Fletcher S, Zhao W, Gunning PT, Turkson J. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol 2010; 79: 1398-1409.
58. Zhang XL, Yue PB, Page BDG, Li TS, Zhao W, Namanja AT et al. Orally bioavailable smallmolecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci USA 2012; 109: 9623-9628.
59. Sethi G, Chatterjee S, Rajendran P, Li F, Shanmugam MK, Wong KF et al. Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Mol Cancer 2014; 13:44.
60. Glienke W, Maute L, Wicht J, Bergmann L. Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/ BIRC5 gene expression. Cancer Invest 2010; 28: 166-171.
61. Pang M, Ma L, Gong R, Tolbert E, Mao H, Ponnusamy M et al. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int 2010; 78: 257-268.
62. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
63. Zhong Z, Wen Z, Darnell JE. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994; 264: 95-98.
64. Zhong Z, Wen ZL, Darnell JE. Stat3 and Stat4-Members of the Family of Signal Transducers and Activators of Transcription. Proc Natl Acad Sci USA 1994; 91: 4806-4810.
65. Abagyan R, Orry A, Rausch E, Budagyan L, Totrov M. ICM Manual, 3.0, MolSoft LLCLa Jolla, CA, USA 2009.
66. Abagyan R, Totrov M. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J Mol Biol 1994; 235: 983-1002.
67. Halgren TA. Merck molecular force field. I-V. J Comput Chem 1996; 17: 490-519.
68. Totrov M, Abagyan R. Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins 1997; Suppl 1: 215-220.
69. Schapira M, Totrov M, Abagyan R. Prediction of the binding energy for small molecules, peptides and proteins. J Mol Recognit 1999; 12: 177-190.
70. Totrov M, Abagyan R. Derivation of senstitive discrimination potential for virtual ligand screening. In:RECOMB '99: Third Annual International Conference on Computational Molecular Biology. Association for Computing Machinery: New York: Lyon, France 1999.